about
Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion StudyAbsence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion.Monitoring the trend of the transmission rate of vertically acquired HIV infection: a simple method applied to Italian data.Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based methodChanges over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study GroupUse of AIDS surveillance data to describe subepidemic dynamics.HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.Acquired immunodeficiency without HIV infection: epidemiology and clinical outcome in Italy. The Italian Study Group on non-HIV AIDS.Response to highly active antiretroviral therapy according to duration of HIV infection.Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?AIDS-related focal brain lesions in the era of highly active antiretroviral therapy.Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study.Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS).Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group.Changing disease patterns in focal brain lesion-causing disorders in AIDS.Multiple imputation method for estimating incidence of HIV infection. The Multicenter Prospective HIV Study.Long-term perspective on the prevalent-cohort biases in studies of human immunodeficiency virus progression.Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. The Human Immunodeficiency Virus Italian Seroconversion Study.Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.Prevalence of IgM and IgG antibodies to West Nile virus among blood donors in an affected area of north-eastern Italy, summer 2009.Tick-borne encephalitis in north-east Italy: a 14-year retrospective study, January 2000 to December 2013.Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study.Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study.Detection of a chikungunya outbreak in Central Italy, August to September 2017.Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias.Peripheral neuropathies among patients with HIV infection.Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study.Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users.Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy.The effect of the 1993 European revision of the AIDS case definition in Italy: implications for modelling the HIV epidemic.Evaluation of symptoms suggestive of HIV acute disease among injecting drug users.Antiretroviral combination therapies and AIDS-defining cancers.Does breast-feeding delay progression to AIDS in HIV-infected children?Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals.
P50
Q28138750-757FFA51-FEB2-4BFA-AD61-21101102F879Q30630850-AD575E15-AF8F-4130-AC05-A21BA288B125Q30664861-E5E6CAC5-4DE2-457B-B9D6-3438F7E66BD3Q33872748-D7101423-C26D-41AE-A287-DDBE7A3EDE54Q33909000-8B194ACA-5821-4FED-A433-3DE08075D0A6Q34438290-7CD49309-DE3D-470A-B3B2-AD253D045A24Q36456737-5F11CD56-4FEB-40C1-80AA-ADF97A724611Q36456737-DCB27117-7FFA-4680-A48C-5BD9D1BC9139Q36600140-6D5C8C6C-0B12-42FA-9E11-285D15B0A0C1Q36789951-CD91C755-244D-42AE-B817-434DF977D22BQ36888435-F64DAFD1-1B89-4CAA-8168-2D6135E1FE18Q36905013-A906A3A3-27C5-4143-BE4B-E67C8BC47CFCQ38493079-1633F235-3396-4E14-9B8D-5B4E063BDDF2Q38493462-9986B18D-C890-4151-9F56-CEC13BE51893Q38495248-B3E9CC0A-82C3-458C-922C-EDB5D4131D76Q38495691-8C0FABF0-C75E-43CB-9507-AF37F57AFF3FQ38498921-AB81580E-9BCF-48CC-89BF-1DBAFCA03110Q38500450-BB2EC25D-C8E7-46CA-B266-FA0D4CAB24DAQ38502208-00E67051-A99C-49A3-AD0A-0A7A9D90A2CCQ38503707-35F0061F-FFB8-4AE5-996F-805D96E09635Q38503871-B951B850-1E60-4E5A-9973-5B3AC249CE89Q38507682-DF33F162-A93F-40D3-BAE0-273F17BE4827Q38959219-F06D0F9C-FAA4-4C35-A623-C01AA77D5DB2Q39262786-EB702036-48A0-45B9-B877-E28110C93DB5Q40329993-14C79A4E-1BE5-49E9-BA34-4D18BC9756C3Q40355453-9CE2CB00-18C1-42ED-8E74-724FABCA4971Q40661997-7FC76F50-8E5D-4276-8126-DCEB15A0B5F8Q40684108-52287CFF-1AC6-43F2-A995-60EEABE97B4CQ41919423-F60CE72D-CD0E-4203-BE91-BEDDE1E44AD9Q42229844-5C92601E-6027-4914-9F5E-ECFEC36A152EQ42786278-944E2A0A-293D-487B-8C3B-4D39EF85733EQ42912080-1C561BB4-8D0B-41A0-BE42-66FAAEF74E7FQ43442033-486274BB-A37E-4789-B231-B19D982FD117Q43608936-CEDA8790-80B8-41F9-9880-360E36A002F4Q43816907-D4CBB820-F96D-45A3-8098-A2C8C7210C97Q43864901-E9ABD8E6-0F0F-4315-8D91-1223372E4278Q43871408-4CD760E4-1363-4FCA-87DA-7E471071D63AQ43999655-EBB2572F-5136-4AFD-A2FB-D13A009D3B4AQ44026845-29C0F3E1-A929-418F-A29A-6578C9D29FB5Q44230234-B166E69D-A41D-40D6-9544-BD5F20940F33
P50
name
Patrizio Pezzotti
@en
type
label
Patrizio Pezzotti
@en
prefLabel
Patrizio Pezzotti
@en